Turnstone Biologics Corp (NASDAQ: TSBX)’s stock price has increased by 11.45 compared to its previous closing price of 2.62. However, the company has seen a 3.91% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-02-21 that SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences: TD Cowen 44 th Annual Global Health Care Conference Type: Presentation and one-on-one investor meetings Speaker: Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer Date: Wednesday, March 6, 2024 Presentation Time: 2:10pm ET / 11:10am PT Location: Boston, MA Leerink Partners Global Biopharma Conference 2024 Type:Date:Location: One-on-one investor meetingsWednesday, March 13, 2024Miami, FL A live webcast of the presentation may be accessed on the Events page of Turnstone’s Investor Relations website at https://ir.turnstonebio.com, where a replay will also be available for a limited period.
Is It Worth Investing in Turnstone Biologics Corp (NASDAQ: TSBX) Right Now?
There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TSBX is 13.21M and currently, short sellers hold a 4.74% ratio of that float. The average trading volume of TSBX on April 23, 2024 was 199.22K shares.
TSBX’s Market Performance
TSBX stock saw a decrease of 3.91% in the past week, with a monthly decline of -12.57% and a quarterly a decrease of 29.78%. The volatility ratio for the week is 10.17%, and the volatility levels for the last 30 days are 14.05% for Turnstone Biologics Corp (TSBX). The simple moving average for the last 20 days is -2.24% for TSBX stock, with a simple moving average of -33.53% for the last 200 days.
Analysts’ Opinion of TSBX
Piper Sandler, on the other hand, stated in their research note that they expect to see TSBX reach a price target of $20. The rating they have provided for TSBX stocks is “Overweight” according to the report published on August 15th, 2023.
BofA Securities gave a rating of “Buy” to TSBX, setting the target price at $18 in the report published on August 15th of the previous year.
TSBX Trading at -7.23% from the 50-Day Moving Average
After a stumble in the market that brought TSBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.88% of loss for the given period.
Volatility was left at 14.05%, however, over the last 30 days, the volatility rate increased by 10.17%, as shares sank -2.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.13% upper at present.
During the last 5 trading sessions, TSBX rose by +3.91%, in comparison to the 20-day moving average, which settled at $2.98. In addition, Turnstone Biologics Corp saw 14.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSBX starting from Jerel Davis, who purchase 225,000 shares at the price of $12.00 back on Jul 25 ’23. After this action, Jerel Davis now owns 2,726,322 shares of Turnstone Biologics Corp, valued at $2,700,000 using the latest closing price.
Versant Ventures V, LLC, the 10% Owner of Turnstone Biologics Corp, purchase 225,000 shares at $12.00 during a trade that took place back on Jul 25 ’23, which means that Versant Ventures V, LLC is holding 2,726,322 shares at $2,700,000 based on the most recent closing price.
Stock Fundamentals for TSBX
Current profitability levels for the company are sitting at:
- -3.06 for the present operating margin
- 1.0 for the gross margin
The net margin for Turnstone Biologics Corp stands at -2.86. The total capital return value is set at -0.59.
Based on Turnstone Biologics Corp (TSBX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -20.58.
Currently, EBITDA for the company is -56.23 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 2.74. The receivables turnover for the company is 99.52for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.57.
Conclusion
In conclusion, Turnstone Biologics Corp (TSBX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
